In:
Blood, American Society of Hematology, Vol. 132, No. Supplement 1 ( 2018-11-29), p. 1627-1627
Kurzfassung:
Introduction Cutaneous T-cell lymphoma (CTCL), a heterogeneous group of rare non-Hodgkin's lymphomas, is characterized by infiltration of malignant clonally expanded T lymphocytes in the skin and is very challenging to treat at advanced stages. Around 65% of the CTCL cases are mycosis fungoides (MF), which usually starts as indolent disease with accumulation of neoplastic resident memory T lymphocytes in the skin, evolving from patch to plaque and later to tumor stage with poor prognosis. Sézary syndrome (SS) involves erythroderma in the skin, malignant circulating clone, and lymphadenopathy. The CTCL pathogenesis is incompletely understood but suggests a complex interplay between neoplastic T cells and the tumor microenvironment. Glycoengineered ARGX-110 potently blocks CD70/CD27 signaling, which is thought to inhibit evasion of tumor immune surveillance as well as tumor cell proliferation and survival. The ARGX-110 effector functions, i.e., complement-dependent cytotoxicity (CDC), antibody-dependent cellular phagocytosis (ADCP), and enhanced antibody-dependent cellular cytotoxicity (ADCC), efficiently kill CD70-expressing tumor cells. With only limited expression in normal tissues and strong expression on tumor cells, CD70 is a very attractive target for antibody-based therapy in cancer. The role of CD70 and treatment with ARGX-110 was further investigated as part of a Phase 1/2 study in advanced CTCL patients. Methods As part of a non-randomized, open-label, multicenter Phase 1/2 study (NCT01813539), a total of 27 patients with CD70-expressing advanced CTCL of different subtypes and stages were included for determination of the optimal dose, to evaluate exploratory efficacy and safety, and to characterize pharmacokinetics and biomarkers of drug activity (immunohistochemistry [IHC] staining for drug- and disease-related markers, profiling of malignant and non-malignant immune cells by flow cytometry, quantitative polymerase chain reaction [qPCR] and Nanostring). ARGX-110 was administered intravenously at 1 (N=11) or 5 mg/kg (N=16) every three weeks (Q3W). Adverse events were graded according to NCI-CTCAE v. 4.03. Results ARGX-110 was safe and well tolerated at both 1 and 5 mg/kg in heavily treated CTCL patients with a median age of 67 years (range: 25-84 years). At cut-off (26th June 2018), a total of 110 treatment-emergent adverse events (TEAE) were reported in 27 patients of which 12 were grade 3-5; 40 events in 18 patients were considered drug-related by the investigator. The most common TEAE was pyrexia (7 events in 5 patients), and infusion-related reactions (IRRs) was the most common drug-related TEAE. The best response was 1 complete response (CR), 5 partial response (PR), and 7 stable disease (SD) in 26/27 patients evaluable for response, meaning overall response (ORR) in 23% of the patients and disease stabilization in 27% of the patients. The mean duration on the study was around 4.8 months. Two patients were still on the study at cut-off: 1 patient (subcutaneous panniculitis-like T-cell lymphoma, 24 months) with CR and 1 SS patient with PR (6.5 months). Pharmacokinetics (PK) revealed a mean half-life of 8-12 days, in line with previously published data. The 5 mg/kg dose was chosen as the recommended phase 2 dose (RP2D) based on PK and immunogenicity data. IHC staining for drug- and disease-specific markers showed results in line with clinical reduction of modified Severity Weighted Assessment Tool (mSWAT) and regression from plaque to patch stages. Molecular and cellular profiling indicated a complex interplay between the tumor and the microenvironment, in which CD70/CD27 plays a role. Conclusions ARGX-110 was safe and well tolerated at both dose levels (1 and 5 mg/kg) in advanced CD70-expressing CTCL patients. Clinical anti-tumor activity in patients with various types of CTCL was observed after treatment with ARGX-110, indicating ARGX-110 as a safe and promising treatment option for advanced CTCL. Disclosures Bagot: Kyowa Kirin: Membership on an entity's Board of Directors or advisory committees; Actelion: Membership on an entity's Board of Directors or advisory committees; Takeda: Membership on an entity's Board of Directors or advisory committees; Innate Pharma: Consultancy, Equity Ownership, Membership on an entity's Board of Directors or advisory committees. Maerevoet:Karyopharm: Membership on an entity's Board of Directors or advisory committees; takeda: Membership on an entity's Board of Directors or advisory committees, Other: travel grant; roche: Other: travel grant; abbvie: Membership on an entity's Board of Directors or advisory committees, Other: travel grant. Zinzani:Celgene: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Bayer: Membership on an entity's Board of Directors or advisory committees; PFIZER: Honoraria, Membership on an entity's Board of Directors or advisory committees; PFIZER: Honoraria, Membership on an entity's Board of Directors or advisory committees; Bayer: Membership on an entity's Board of Directors or advisory committees; Takeda: Membership on an entity's Board of Directors or advisory committees; MSD: Honoraria, Speakers Bureau; Janssen: Honoraria, Speakers Bureau; Celltrion: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Astra Zeneca: Speakers Bureau; TG Pharmaceuticals: Honoraria, Membership on an entity's Board of Directors or advisory committees; Gilead: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Roche: Honoraria, Membership on an entity's Board of Directors or advisory committees; Merck: Honoraria, Membership on an entity's Board of Directors or advisory committees; BMS: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Merck: Honoraria, Membership on an entity's Board of Directors or advisory committees; Verastem: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; TG Pharmaceuticals: Honoraria, Membership on an entity's Board of Directors or advisory committees; SERVIER: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Morschhauser:Janssen: Other: Scientific Lectures; Epizyme: Consultancy; Roche: Membership on an entity's Board of Directors or advisory committees; BMS: Membership on an entity's Board of Directors or advisory committees; Celgene: Consultancy, Membership on an entity's Board of Directors or advisory committees; Gilead: Consultancy, Membership on an entity's Board of Directors or advisory committees. Ribrag:Incyte Corporation: Consultancy; Amgen: Research Funding; Infinity: Consultancy, Honoraria; Gilead: Consultancy, Honoraria; epizyme: Consultancy, Honoraria; NanoString Technologies: Consultancy, Honoraria; Roche: Honoraria, Other: travel; Servier: Consultancy, Honoraria; pharmamar: Other: travel; argenX: Research Funding; BMS: Consultancy, Honoraria, Other: travel; MSD: Honoraria. Dalle:Kyowa Hakko Kirin Pharmaceutical: Research Funding. Cayuela:Cepheid: Other: financial sponsor to attend John Goldman Conference 2017. Hultberg:argenx: Employment. Gandini:argenx: Employment. Moshir:argenx: Employment. Delahaye:argenx: Employment. Zabrocki:argenx: Employment. Silence:argenx: Consultancy. Van Rompaey:argenx: Employment. De Haard:argenx: Employment. Leupin:argenx: Employment.
Materialart:
Online-Ressource
ISSN:
0006-4971
,
1528-0020
DOI:
10.1182/blood-2018-99-118204
Sprache:
Englisch
Verlag:
American Society of Hematology
Publikationsdatum:
2018
ZDB Id:
1468538-3
ZDB Id:
80069-7
